•Fear of cancer recurrence (#FCR) is *normal* and incredibly common. •For some it leads to excessive #worry and #symptom monitoring, and significantly interrupts their lives. •Importantly, for many people the FCR doesn’t go away - it #persists over time. #IPOS2019

So happy to see well designed interventions targeting #FCR successfully presented IPOS. All the more exciting to present a #nullfinding trial at the beginning of the #IPOS2019 congress. You’ll find me at Kinnearcentre Galleria-Level 3 today. 1/15

Thank you #IPOS2019 for the opportunity to present my research on #symptom perception in #AYAcancer survivors today. My first #betterposter design was seemingly a success :)

Ever wonder if psychosocial interventions are cost effective or how to 'sell' them to decision-makers? Come to our #FCR #FearofCancerRecurrence symposium today at 9:45 to find out more. Dream research team Dr. Nadine Kasparian Judith prins Louise Sharpe Josée Savard

This should be great! #IPOS2019 #FCR research

Next speaker is judith.b.prins 🇳🇱 about cost-effectiveness of the SWORD #FCR blended intervention. Selected with cancer worry scale >-14. 42% had clinical significant change compared to 10% in control CAU. #IPOS2019

Another effective intervention for #FCR the SWORD trial judith.b.prins #IPOS2019

With 80% likelihood it is cost-effective. More analysis including both medical and non medical costs (loss of positivity e.g.) and included costs of therapist and online platform licenses. They used most conservative willing to pay threshold (20.000€). #IPOS2019

62-95% probability that BCBT is more cost effective than the threshold of willingness to pay. But we could not conclude that BCBT is more cost effective than CAU. When implemented in clinical care or will probably become more cost effective. #IPOS2019

On the third floor today ⁦José Custers⁩ with a beautiful poster on #FoP on a new group of pts, please come over. #IPOS2019

A great initiative by Dr. Custers to better define fear of progression in the growing population of patients with advanced cancer #IPOS2019 #FCR

Great poster and am loving vlogs to summarise important findings. More please!!!! #IPOS2019 IPOS

Depression but not anxiety at baseline predicts fatigue 12 months later in ovarian and endometrial cancers #IPOS2019

The situation is NOT improving for indigenous people, with increasing disparities in survival between indigenous and nonindigenous Australians. #IPOS2019

Incredibly grateful to have had the opportunity to present at the International Psycho-Oncology Society World Congress in breathtaking Banff. Even better, I got to discuss my research with world leaders in the field as well as patients and advocates. Heart=full. #IPOS2019

Prof. dr. Thijs Merkx wordt de nieuwe voorzitter van de raad van bestuur van #IKNL. iknl.nl/over-iknl/nieu…

📢📢The submission deadline for #ICBM2023 has now been extended to December 10!📢📢 You can find the submission page here: bit.ly/3TTzLu8

Want to meet editors of #Behavioralmedicine at our #ICBM2023 conference in #Vancouver, Canada Sheraton Vancouver Wall Centre? This is your chance to meet the #Editor- in-Chief of International Journal of Behavioral Medicine! Submit your abstract by Dec 10th at icbm2023.com/program/call-f…

Honored & grateful for receiving the Hiroomi & Setsuko Kawano New Investigator Award. Many thanks to my research team, students, colleagues and research participants. Special thanks to judith.b.prins Dr.SophieLebel 🇨🇦 Marije van der Lee for nominating me. IPOS Radboudumc